PolyPeptide Group AG Statistics

Total Valuation

PolyPeptide Group AG has a market cap or net worth of GBP 765.80 million. The enterprise value is 823.80 million.

Market Cap	765.80M
Enterprise Value	823.80M

Important Dates

The next estimated earnings date is Tuesday, March 11, 2025.

Earnings Date	Mar 11, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-0.61%
Shares Change (QoQ)	-1.38%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	12.96M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	2.63
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 218.89, with an EV/FCF ratio of 29.36.

EV / Earnings	-34.02
EV / Sales	2.96
EV / EBITDA	218.89
EV / EBIT	n/a
EV / FCF	29.36

Financial Position

The company has a current ratio of 1.59, with a Debt / Equity ratio of 0.32.

Current Ratio	1.59
Quick Ratio	0.64
Debt / Equity	0.32
Debt / EBITDA	26.51
Debt / FCF	3.50
Interest Coverage	-2.48

Financial Efficiency

Return on equity (ROE) is -7.68% and return on invested capital (ROIC) is -3.09%.

Return on Equity (ROE)	-7.68%
Return on Assets (ROA)	-2.34%
Return on Capital (ROIC)	-3.09%
Revenue Per Employee	214,830
Profits Per Employee	-18,961
Employee Count	1,273
Asset Turnover	0.52
Inventory Turnover	1.98

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +83.23% in the last 52 weeks. The beta is 1.12, so PolyPeptide Group AG's price volatility has been higher than the market average.

Beta (5Y)	1.12
52-Week Price Change	+83.23%
50-Day Moving Average	28.40
200-Day Moving Average	30.14
Relative Strength Index (RSI)	43.72
Average Volume (20 Days)	506

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, PolyPeptide Group AG had revenue of GBP 274.34 million and -24.21 million in losses. Loss per share was -0.74.

Revenue	274.34M
Gross Profit	14.58M
Operating Income	-19.87M
Pretax Income	-26.56M
Net Income	-24.21M
EBITDA	378,975
EBIT	-19.87M
Loss Per Share	-0.74

Full Income Statement

Balance Sheet

The company has 41.10 million in cash and 98.19 million in debt, giving a net cash position of -57.09 million.

Cash & Cash Equivalents	41.10M
Total Debt	98.19M
Net Cash	-57.09M
Net Cash Per Share	n/a
Equity (Book Value)	305.14M
Book Value Per Share	9.25
Working Capital	92.44M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 72.30 million and capital expenditures -44.24 million, giving a free cash flow of 28.06 million.

Operating Cash Flow	72.30M
Capital Expenditures	-44.24M
Free Cash Flow	28.06M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 5.32%, with operating and profit margins of -7.24% and -8.83%.

Gross Margin	5.32%
Operating Margin	-7.24%
Pretax Margin	-9.68%
Profit Margin	-8.83%
EBITDA Margin	0.14%
EBIT Margin	-7.24%
FCF Margin	10.23%

Dividends & Yields

PolyPeptide Group AG does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.61%
Shareholder Yield	0.61%
Earnings Yield	-3.16%
FCF Yield	3.66%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

PolyPeptide Group AG has an Altman Z-Score of 2.36. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.36
Piotroski F-Score	n/a